UL Prospector
Prospector

CelluCap™ RL

  • 会社:

    Tagra Biotechnologies Ltd.

  • INCI名:

    Pentaerythrityl Tetra-di-t-butyl Hydroxyhydrocinnamate (and) Retinol (and) Cellulose Acetate Butyrate (and) Tricaprylin

CelluCap™ RL’s encapsulated Retinol is easily released upon mechanical pressure, such as a rubbing action. The single layer polymeric shell collapses and breaks down into invisible particles, but still retains the payload to continue and deliver over time. Until the moment of application, Retinol remains fresh and potent. Retinol is highly recognized as a very effective vitamin for anti-aging treatment due to its capacity to stimulate collagen production, accelerate cell reproduction and normalize skin keratinization. Its regular application significantly improves skin elasticity, smoothness, and softness, resulting in younger, clearer and healthier looking skin. Nevertheless, Retinol is highly sensitive to oxidation, degradation in the presence of air, sunlight, acidic conditions and heavy metals which results in decreased efficacy and formula discoloration. Tagra Biotechnologies overcomes these challenges with CelluCap™ RL. By delivering stabilized pure Retinol in a microencapsulation, Tagra helps to improve the performance and shelf life of the final formula.

Upgrade to Prospector Premium to view Compliance Highlights 詳細はこちら

Retailer Compliance Status

No retailer information is available at this time.

Regulatory & Advisory Status

現在の時点で規制情報はありません。

Compliance information powered by UL's ChemADVISOR™ Regulatory Database.

会社

Tagra Biotechnologies, since its inception in 1998, focuses on developing and manufacturing microencapsulated ingredients such as actives, pigments, essential oils, UV filters, and highly water-soluble ingredients.

Tagra is the first to patent a unique innovative Release on Demand™ (RND™) Microencapsulation Technology. Tagra’s platform addresses industry challenges of stability, efficiency, and compatibility with other cosmetic and pharmaceutical formulation ingredients. The technology enables the masking, protecting, and releasing of more than 40 actives and pigments widely used in cosmetics and OTC preparations. Tagra’s microcapsules are friction released through consumer applications.

Tagra also owns and operates its own plant and state-of-the-art laboratory meeting all required regulations.

サプライヤ資料

ここに表示されるカテゴリは、ULが材料の生産者から入手した情報に基づいています。  ULはこのデータの正確さを保証するために十分な努力を払っています。  ただし、データの値について、ULは責任を負いません。したがって、最終的な材料選択のためのデータに関しては、材料のサプライヤーに確認することを強くお勧めします。

Tagra Biotechnologies Ltd. makes their documentation available in the regions indicated below:

販売店

Tagra Biotechnologies Ltd.

お客様はここへのリスティングを希望する販売店ですか。 問い合わせる